Cargando…
SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people
Understanding vaccine-mediated protection against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is critical to overcoming the global coronavirus disease 2019 (COVID-19) pandemic. We investigate mRNA-vaccine-induced antibody responses against the reference strain, seven variants, and s...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s).
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769879/ https://www.ncbi.nlm.nih.gov/pubmed/35090596 http://dx.doi.org/10.1016/j.celrep.2022.110336 |
_version_ | 1784635242217209856 |
---|---|
author | Narowski, Tara M. Raphel, Kristin Adams, Lily E. Huang, Jenny Vielot, Nadja A. Jadi, Ramesh de Silva, Aravinda M. Baric, Ralph S. Lafleur, John E. Premkumar, Lakshmanane |
author_facet | Narowski, Tara M. Raphel, Kristin Adams, Lily E. Huang, Jenny Vielot, Nadja A. Jadi, Ramesh de Silva, Aravinda M. Baric, Ralph S. Lafleur, John E. Premkumar, Lakshmanane |
author_sort | Narowski, Tara M. |
collection | PubMed |
description | Understanding vaccine-mediated protection against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is critical to overcoming the global coronavirus disease 2019 (COVID-19) pandemic. We investigate mRNA-vaccine-induced antibody responses against the reference strain, seven variants, and seasonal coronaviruses in 168 healthy individuals at three time points: before vaccination, after the first dose, and after the second dose. Following complete vaccination, both naive and previously infected individuals developed comparably robust SARS-CoV-2 spike antibodies and variable levels of cross-reactive antibodies to seasonal coronaviruses. However, the strength and frequency of SARS-CoV-2 neutralizing antibodies in naive individuals were lower than in previously infected individuals. After the first vaccine dose, one-third of previously infected individuals lacked neutralizing antibodies; this was improved to one-fifth after the second dose. In all individuals, neutralizing antibody responses against the Alpha and Delta variants were weaker than against the reference strain. Our findings support future tailored vaccination strategies against emerging SARS-CoV-2 variants as mRNA-vaccine-induced neutralizing antibodies are highly variable among individuals. |
format | Online Article Text |
id | pubmed-8769879 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Author(s). |
record_format | MEDLINE/PubMed |
spelling | pubmed-87698792022-01-20 SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people Narowski, Tara M. Raphel, Kristin Adams, Lily E. Huang, Jenny Vielot, Nadja A. Jadi, Ramesh de Silva, Aravinda M. Baric, Ralph S. Lafleur, John E. Premkumar, Lakshmanane Cell Rep Article Understanding vaccine-mediated protection against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is critical to overcoming the global coronavirus disease 2019 (COVID-19) pandemic. We investigate mRNA-vaccine-induced antibody responses against the reference strain, seven variants, and seasonal coronaviruses in 168 healthy individuals at three time points: before vaccination, after the first dose, and after the second dose. Following complete vaccination, both naive and previously infected individuals developed comparably robust SARS-CoV-2 spike antibodies and variable levels of cross-reactive antibodies to seasonal coronaviruses. However, the strength and frequency of SARS-CoV-2 neutralizing antibodies in naive individuals were lower than in previously infected individuals. After the first vaccine dose, one-third of previously infected individuals lacked neutralizing antibodies; this was improved to one-fifth after the second dose. In all individuals, neutralizing antibody responses against the Alpha and Delta variants were weaker than against the reference strain. Our findings support future tailored vaccination strategies against emerging SARS-CoV-2 variants as mRNA-vaccine-induced neutralizing antibodies are highly variable among individuals. The Author(s). 2022-02-01 2022-01-20 /pmc/articles/PMC8769879/ /pubmed/35090596 http://dx.doi.org/10.1016/j.celrep.2022.110336 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Narowski, Tara M. Raphel, Kristin Adams, Lily E. Huang, Jenny Vielot, Nadja A. Jadi, Ramesh de Silva, Aravinda M. Baric, Ralph S. Lafleur, John E. Premkumar, Lakshmanane SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people |
title | SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people |
title_full | SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people |
title_fullStr | SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people |
title_full_unstemmed | SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people |
title_short | SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people |
title_sort | sars-cov-2 mrna vaccine induces robust specific and cross-reactive igg and unequal neutralizing antibodies in naive and previously infected people |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769879/ https://www.ncbi.nlm.nih.gov/pubmed/35090596 http://dx.doi.org/10.1016/j.celrep.2022.110336 |
work_keys_str_mv | AT narowskitaram sarscov2mrnavaccineinducesrobustspecificandcrossreactiveiggandunequalneutralizingantibodiesinnaiveandpreviouslyinfectedpeople AT raphelkristin sarscov2mrnavaccineinducesrobustspecificandcrossreactiveiggandunequalneutralizingantibodiesinnaiveandpreviouslyinfectedpeople AT adamslilye sarscov2mrnavaccineinducesrobustspecificandcrossreactiveiggandunequalneutralizingantibodiesinnaiveandpreviouslyinfectedpeople AT huangjenny sarscov2mrnavaccineinducesrobustspecificandcrossreactiveiggandunequalneutralizingantibodiesinnaiveandpreviouslyinfectedpeople AT vielotnadjaa sarscov2mrnavaccineinducesrobustspecificandcrossreactiveiggandunequalneutralizingantibodiesinnaiveandpreviouslyinfectedpeople AT jadiramesh sarscov2mrnavaccineinducesrobustspecificandcrossreactiveiggandunequalneutralizingantibodiesinnaiveandpreviouslyinfectedpeople AT desilvaaravindam sarscov2mrnavaccineinducesrobustspecificandcrossreactiveiggandunequalneutralizingantibodiesinnaiveandpreviouslyinfectedpeople AT baricralphs sarscov2mrnavaccineinducesrobustspecificandcrossreactiveiggandunequalneutralizingantibodiesinnaiveandpreviouslyinfectedpeople AT lafleurjohne sarscov2mrnavaccineinducesrobustspecificandcrossreactiveiggandunequalneutralizingantibodiesinnaiveandpreviouslyinfectedpeople AT premkumarlakshmanane sarscov2mrnavaccineinducesrobustspecificandcrossreactiveiggandunequalneutralizingantibodiesinnaiveandpreviouslyinfectedpeople |